New gout pill combined with febuxostat for high uric acid
Treatments studied
Part of Bones, joints & muscles, Hormones & metabolism, Kidney & urinary clinical trials.
This trial tests an experimental tablet (SHR4640) added to the standard gout medicine febuxostat (40 mg daily) for people whose uric acid remains too high despite febuxostat alone. The goal is to see if the combination lowers uric acid more effectively and safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been taking febuxostat 40 mg daily for at least 6 weeks before joining.
- Your fasting uric acid level must be at least 390 µmol/L (first test) and then at least 360 µmol/L on a repeat test while taking febuxostat.
- You must have a diagnosis of gout according to standard medical criteria.
- You must have a body mass index (BMI) between 18 and 35.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called tigulixostat against febuxostat, a standard gout treatment, to see which works better at lowering uric acid levels. You may qualify if you have gout with high uric acid and have not had a gout flare in the last month.
This trial tests an experimental drug, SSS11, to see if it is safe and how it affects uric acid levels in people with gout and high uric acid. You may not take other gout medicines during the study.
This trial tests a new tablet (HR091506) for adults with gout and high uric acid. It aims to lower uric acid levels and reduce gout attacks, especially for people with more severe gout (like tophi or frequent attacks).
This trial tests a new tablet called BR2251 for people with gout and high uric acid. It aims to lower uric acid levels and manage gout symptoms.
This trial tests if gradually lowering the dose of the gout medication febuxostat is safe for people whose gout has been well-controlled for at least 5 years. The goal is to see if a lower dose can still keep uric acid levels in a healthy range.
This study tests if a new drug, ABP-671, can safely lower high uric acid levels in people with chronic kidney disease. It may help reduce gout attacks and kidney damage.
Hear when a new Primary Gout and Hyperuricemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.